EDDING GENOR (06998): First-in-human Phase I clinical study data for GB268 released at the 2026 ESMO Congress
Edding Genor (06998) announced that preliminary data from the first-in-human Phase I clinical study of GB268 have been released in poster form at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No.: 1963P). The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors.
EDDING GENOR (06998) announced that preliminary data from the first-in-human Phase I clinical study of GB268 were released in poster form at the 2026 European Society for Medical Oncology (ESMO) Congress (Abstract No.: 1963P). The study evaluated the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of GB268 monotherapy in patients with previously treated advanced solid tumors.
Related Articles
US Stock Market Move | SLB (SLB.US) rises nearly 7%, Q3 production systems revenue up 15% year-over-year.
AI shopping assistants disrupt the e-commerce landscape! Bernstein: It may be a wise move for platforms such as Amazon.com, Inc. (AMZN.US) and Uber Technologies, Inc. (UBER.US) to temporarily refuse access.
Shenwan Hongyuan Group Hong Kong (00218): The Group's core businesses such as trading and settlement, as well as its management systems, are all operating normally, and all businesses are being carried out as usual.
US Stock Market Move | SLB (SLB.US) rises nearly 7%, Q3 production systems revenue up 15% year-over-year.
AI shopping assistants disrupt the e-commerce landscape! Bernstein: It may be a wise move for platforms such as Amazon.com, Inc. (AMZN.US) and Uber Technologies, Inc. (UBER.US) to temporarily refuse access.
Shenwan Hongyuan Group Hong Kong (00218): The Group's core businesses such as trading and settlement, as well as its management systems, are all operating normally, and all businesses are being carried out as usual.
